The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Evaluation of chemotherapy response in pediatric bone sarcomas by [F‐18]‐fluorodeoxy‐D‐glucose positron emission tomography
Open accessAbstract
BACKGROUND: Response to neoadjuvant chemotherapy is a significant prognostic factor for osteosarcoma (OS) and the Ewing sarcoma family of tumors (ESFT). Conventional radiographic imaging does not discriminate between responding and nonresponding osseous tumors. [F‐18]‐fluorodeoxy‐D‐glucose (FDG) positron emission tomography (PET) is a noninvasive imaging modality that accurately predicts histopathologic response in patients with various malignancies. To describe the FDG PET imaging characteristics and to determine the correlation between FDG PET imaging and chemotherapy response in children with bone sarcomas, we reviewed our single institution experience. METHODS: Thirty‐three pediatric patients with OS or ESFT with osseous primary sites were evaluated by FDG PET. All patients received standard neoadjuvant chemotherapy. FDG PET standard uptake values before (SUV1) and after (SUV2) chemotherapy were analyzed and correlated with chemotherapy response assessed by histopathology in surgically excised tumors. Twenty‐six patients had SUV1, SUV2, and surgical excision. RESULTS: Although the mean SUV1 in children with OS or ESFT were similar (8.2. vs. 5.3, P = 0.13), mean SUV2 for OS patients was greater than the values for ESFT patients (3.3 vs. 1.5, P = 0.01). All ESFT patients and 28% of OS patients had a favorable histologic response to chemotherapy (≥ 90% necrosis). Combining ESFT and OS patients, both SUV2 and the ratio of SUV2 to SUV1 (SUV2:SUV1) were correlated with histologic response (P = 0.01 for both comparisons). CONCLUSION: FDG PET evaluation of pediatric bone sarcomas demonstrated significant alteration in response to neoadjuvant chemotherapy. SUV2 and SUV2:SUV1 correlated with histopathologic assessment of response and potentially could be used as a noninvasive surrogate to predict response in patients. Cancer 2002;94:3277–84. © 2002 American Cancer Society. DOI 10.1002/cncr.10599
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meyers, P. A., & Gorlick, R. (1997) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70540-x · Cited by 299
Cited by
Bastiaannet, E., Groen, H., Jager, P. L., Cobben, D. C. P., van der Graaf, W. T. A., Vaalburg, W., & Hoekstra, H. J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.004 · Cited by 294
Hawkins, D. S., Schuetze, S. M., Butrynski, J. E., Rajendran, J. G., Vernon, C. B., Conrad, E. U., & Eary, J. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.7079 · Cited by 286
Self-citationTherapy for Osteosarcoma: Where Do We Go From Here?
Chou, A. J., Geller, D. S., & Gorlick, R. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810050-00005 · Cited by 274
Meyer, J. S., Nadel, H. R., Marina, N., Womer, R. B., Brown, K. L. B., Eary, J. F., Gorlick, R., Grier, H. E., Randall, R. L., Lawlor, E. R., et al. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21596 · Cited by 180
Self-citationShah, A. T., Azad, T. D., Breese, M. R., Chabon, J. J., Hamilton, E. G., Straessler, K., Kurtz, D. M., Leung, S. G., Spillinger, A., Liu, H.-Y., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0987 · Cited by 42
Metadata
- Authors
- Hawkins, D. S., Rajendran, J. G., Conrad, E. U., Bruckner, J. D., & Eary, J. F.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2002-06-12
- Volume
- 94
- Issue
- 12
- Pages
- 3277-3284
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2056019019
- Cited by
- 257
- References
- 1
- FWCI
- 9.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of chemotherapy response in pediatric bone sarcomas by [F‐18]‐fluorodeoxy‐D‐glucose positron emission tomography. https://app.cochat.ai/papers/10.1002/cncr.10599
- The paper
- Hawkins, D. S., Rajendran, J. G., Conrad, E. U., Bruckner, J. D., & Eary, J. F. (2002). Evaluation of chemotherapy response in pediatric bone sarcomas by [F‐18]‐fluorodeoxy‐D‐glucose positron emission tomography. Cancer. https://doi.org/10.1002/cncr.10599
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
